1 Min Read
May 2 (Reuters) - Vical Inc
* Vical highlights successful outcome of Phase 1 trial of VL-2397 novel antifungal during its research and development day Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.